DexCom, Inc. (DXCM)
69.23 USD +1.84 (+2.73%) Volume: 4.61M
With a notable increase of +2.73% in today’s trading session, DexCom, Inc.’s stock price sits at 69.23 USD, despite a YTD decrease of -10.98%. This prominent medical device company is experiencing a high trading volume of 4.61M, indicating significant market interest. Stay updated on DXCM’s dynamic performance.
Latest developments on DexCom, Inc.
Today, Dexcom Inc‘s stock price experienced movements following key events in the market. RBC recently cut their price target on DexCom to $100 from $115 while maintaining an Outperform rating. Additionally, BTIG adjusted DexCom’s price target ahead of the MedTech Q1 results, impacting the stock’s performance. These developments have influenced investors’ sentiments and contributed to the fluctuations in Dexcom Inc‘s stock price today.
DexCom, Inc. on Smartkarma
Analysts at Baptista Research have been closely monitoring Dexcom Inc‘s performance and growth trajectory. In their recent report titled “Dexcom Inc.: Will Sensor Tech Advancements Solidify Its Lead In Continuous Glucose Monitoring?”, the analysts express a bullish sentiment towards the company. DexCom Inc.’s latest earnings for the fourth quarter of 2024 indicate strategic growth and investment, with an 8% organic revenue growth year-over-year. The company’s customer base also saw a significant increase of approximately 25% to over 2.8 million globally, driving this growth.
Furthermore, Baptista Research delves deeper into Dexcom Inc‘s potential future performance in their report “DexCom Inc.: These Are The 7 Biggest Factors Driving Its Performance In 2025 & Beyond! – Major Drivers”. Despite facing challenges in the market dynamics, Dexcom’s strategic and operational updates present a mix of achievements and hurdles. The analysts at Baptista Research aim to evaluate these factors that could impact the company’s stock price in the near future. They also utilize a Discounted Cash Flow (DCF) methodology to conduct an independent valuation of Dexcom Inc, providing valuable insights for investors.
A look at DexCom, Inc. Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 1 | |
Growth | 5 | |
Resilience | 4 | |
Momentum | 4 | |
OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Dexcom Inc seems to have a positive long-term outlook. The company scores high in growth, resilience, and momentum, indicating a strong performance in these areas. With a focus on continuous glucose monitoring systems for people with diabetes, Dexcom Inc‘s innovative technology and consistent growth potential are key factors contributing to its high score in growth.
Although Dexcom Inc may not score as high in value and dividend, its strong performance in growth, resilience, and momentum bodes well for the company’s future prospects. As a medical device company dedicated to improving the lives of individuals with diabetes, Dexcom Inc‘s focus on innovation and product development positions it well for long-term success in the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars